F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-01-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4519-20260129-01.pdf","jir_short_summary":"F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.","jir_summary":"### Regarding F. Hoffmann-La Roche Ltd.'s Financial Results Announcement\nF. Hoffmann-La Roche Ltd. (headquartered in Basel, Switzerland) has announced its fiscal 2025 financial results. Chugai Pharmaceutical is a subsidiary of Roche Holdings, which holds 59.89% of Chugai Pharmaceutical\u2019s issued shares (voting rights ratio of 61.12%). The performance of the Roche Group includes Chugai Pharmaceutical\u2019s results from January 1, 2025 to December 31, 2025.\n\n### Information for Investors and Future Reference\nDetailed financial materials regarding this matter are available on the official Roche Group website (https:\/\/www.roche.com). Since the parent company's performance affects consolidated results, investors are advised to refer to the parent company\u2019s financial information. Detailed standalone performance figures for Chugai Pharmaceutical are not included in this document.","jir_financial_highlights":"Shareholding Ratio of Issued Shares: 59.89% (Unknown)\nVoting Rights Ratio: 61.12% (Unknown)\nPerformance Period of Roche Group: January 1, 2025 to December 31, 2025 (Unknown)","jir_category":"","jir_hashtags":"#ChugaiPharmaceuticalCoLtd, #general_ir, #JapaneseStocks","jir_key_figures":"Shareholding Ratio of Issued Shares: 59.89% (as of end of December 2025)\nVoting Rights Ratio: 61.12% (as of end of December 2025)\nPerformance Period of Roche Group: January 1, 2025 to December 31, 2025","jir_meta_title":"Chugai Pharmaceutical: Announcement of F. Hoffmann-La Roche Ltd.'s Fiscal 2025 Financial Results","jir_meta_description":"F. Hoffmann-La Roche Ltd., the parent company of Chugai Pharmaceutical, has announced its fiscal 2025 financial results. Chugai holds 59.89% of issued shares, influencing consolidated performance; investors should refer to the parent company's financial information.","jir_og_title":"Announcement of F. Hoffmann-La Roche Ltd.'s Fiscal 2025 Financial Results","jir_og_description":"Roche, the parent company of Chugai Pharmaceutical, announced its fiscal 2025 financial results. Holding 59.89% of issued shares, the group\u2019s performance is attracting attention.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-21623","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n